ArticleTranslational pediatrics2025
Genetic markers and canonical pathways associated with medulloblastoma: a systematic review and meta-analysis.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medulloblastoma is the most common malignant brain tumor of childhood, accounting for 25% of pediatric central nervous system (CNS) neoplasms. Although the cause of medulloblastoma is unclear, recent findings have contributed to treatment guidelines that emphasize the extent of disease, tumor resection margins, and age of onset. This study synthesizes available evidence to provide further insight into associated genetic markers and associated pathways that may be leveraged for individualized therapy. Methods: The Search Tag Analyze Resource for NCBI's Gene Expression Omnibus (STARGEO) was utilized to identify 480 medulloblastoma tumor samples and 62 healthy adult and pediatric cerebellum samples. Pathway analysis was conducted using Ingenuity Pathway Analysis (IPA) and restricted to genes with a statistically significant difference (P<0.05) between medulloblastoma and control and an absolute experimental log ratio greater than 0.2. Results: Overall, 4,142 genes met the inclusion criteria. Genes previously described in the context of medulloblastoma, such as Conclusions: Utilizing STARGEO is an effective method for leveraging genomics metadata to highlight novel and previously described pathways and regulators associated with medulloblastoma. By providing an enhanced understanding of the pathophysiology of medulloblastoma, this study provides a framework for future validation studies-the next step toward identifying target genes and biomarkers for screening, prognostication, and targeted treatment for medulloblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.